Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice

Gene Therapy volume 13, pages 1300–1308 (2006)Cite this article

Abstract

Adeno-associated viral (AAV) vectors promote long-term gene transfer into muscle in many animal species. Increased expression levels may be obtained by using alternative serotypes in combination with repeated administrations. Here we compared AAV vectors based on serotypes 1, 2 and 5 in immunocompetent mice and assessed the feasibility of multiple administrations of either identical (readministration) or different (cross-administration) serotype-based vectors. A 1-year-long dose–response study confirmed the superiority of recombinant (r)AAV1, achieving transduction levels 5 to 10-fold higher than rAAV2 and rAAV5 in mouse skeletal muscle, respectively. Repeated administration demonstrated that increased gene transfer level was achieved with a second injection of rAAV1 following the first administration of rAAV2 or rAAV5. A readministration study with a vector encoding a different gene allowed the evaluation of gene expression from the second vector only. All three rAAVs were inhibited when the animals were previously exposed to the same serotype. In contrast, no significant change in gene expression from the second vector was observed in cross-administration. A humoral immune response was elicited against the viral capsid for all three serotypes following the initial exposure. Neutralizing antibody (NAB) levels correlated with the vector dose injected. No significant cross-reactivity of NAB from a given serotype toward another was observed in vitro. These data provide the first direct comparative evaluation of re- and cross-administration of rAAV1, rAAV2 and rAAV5 in muscle, and further indicate that rAAV1 is capable of transducing muscle tissue when cross-administered.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996; 93: 14082–14087.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Xiao X, Li J, Samulski RJ . Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098–8108.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Xiao X, Li J, Tsao YP, Dressman D, Hoffman EP, Watchko JF . Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 2000; 74: 1436–1442.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kaspar BK, Roth DM, Lai NC, Drumm JD, Erickson DA, McKirnan MD et al. Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus. J Gene Med 2005; 7: 316–324.

    Article  CAS  PubMed  Google Scholar 

  5. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005; 105: 1424–1430.

    Article  CAS  PubMed  Google Scholar 

  6. Greelish JP, Su LT, Lankford EB, Burkman JM, Chen H, Konig SK et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 1999; 5: 439–443.

    Article  CAS  PubMed  Google Scholar 

  7. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257–261.

    Article  CAS  PubMed  Google Scholar 

  8. Flotte TR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT, Baker DJ et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004; 15: 93–128.

    Article  PubMed  Google Scholar 

  9. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3: 306–312.

    Article  CAS  PubMed  Google Scholar 

  10. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963–2972.

    Article  CAS  PubMed  Google Scholar 

  11. Chirmule N, Xiao W, Truneh A, Schnell MA, Hughes JV, Zoltick P et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74: 2420–2425.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Manning WC, Zhou S, Bland MP, Escobedo JA, Dwarki V . Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Ther 1998; 9: 477–485.

    Article  CAS  PubMed  Google Scholar 

  13. Halbert CL, Standaert TA, Wilson CB, Miller AD . Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 1998; 72: 9795–9805.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000; 74: 1761–1766.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chao H, Monahan PE, Liu Y, Samulski RJ, Walsh CE . Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther 2001; 4: 217–222.

    Article  CAS  PubMed  Google Scholar 

  16. Fraites Jr TJ, Schleissing MR, Shanely RA, Walter GA, Cloutier DA, Zolotukhin I et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002; 5: 571–578.

    Article  CAS  PubMed  Google Scholar 

  17. Arruda VR, Schuettrumpf J, Herzog RW, Nichols TC, Robinson N, Lotfi Y et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 2004; 103: 85–92.

    Article  CAS  PubMed  Google Scholar 

  18. Hauck B, Xiao W . Characterization of tissue tropism determinants of adeno-associated virus type 1. J Virol 2003; 77: 2768–2774.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 2004; 10: 671–678.

    Article  CAS  PubMed  Google Scholar 

  20. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321–328.

    Article  CAS  PubMed  Google Scholar 

  21. Erles K, Sebokova P, Schlehofer JR . Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59: 406–411.

    Article  CAS  PubMed  Google Scholar 

  22. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J . Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 1999; 6: 1574–1583.

    Article  CAS  PubMed  Google Scholar 

  23. Parks R, Evelegh C, Graham F . Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Therapy 1999; 6: 1565–1573.

    Article  CAS  PubMed  Google Scholar 

  24. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM . Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73: 3994–4003.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Muramatsu S, Mizukami H, Young NS, Brown KE . Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 1996; 221: 208–217.

    Article  CAS  PubMed  Google Scholar 

  26. Chiorini JA, Yang L, Liu Y, Safer B, Kotin RM . Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 1997; 71: 6823–6833.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Chiorini JA, Kim F, Yang L, Kotin RM . Cloning and characterization of adeno-associated virus type 5. J Virol 1999; 73: 1309–1319.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM . Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854–11859.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78: 6381–6388.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mori S, Wang L, Takeuchi T, Kanda T . Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 2004; 330: 375–383.

    Article  CAS  PubMed  Google Scholar 

  31. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE . Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619–623.

    Article  CAS  PubMed  Google Scholar 

  32. Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM . Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001; 75: 6199–6203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Tobiasch E, Burguete T, Klein-Bauernschmitt P, Heilbronn R, Schlehofer JR . Discrimination between different types of human adeno-associated viruses in clinical samples by PCR. J Virol Methods 1998; 71: 17–25.

    Article  CAS  PubMed  Google Scholar 

  34. Gao G, Alvira MR, Somanathan S, Lu Y, Vandenberghe LH, Rux JJ et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci USA 2003; 100: 6081–6086.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003; 102: 2412–2419.

    Article  CAS  PubMed  Google Scholar 

  36. Jooss K, Yang Y, Fisher KJ, Wilson JM . Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212–4223.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Zhang Y, Chirmule N, Gao G, Wilson J . CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J Virol 2000; 74: 8003–8010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Sarukhan A, Soudais C, Danos O, Jooss K . Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors. J Gene Med 2001; 3: 260–270.

    Article  CAS  PubMed  Google Scholar 

  39. Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW . Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Therapy 2005; 12: 1453–1464.

    Article  CAS  PubMed  Google Scholar 

  40. Xiao W, Chirmule N, Schnell MA, Tazelaar J, Hughes JV, Wilson JM . Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther 2000; 1: 323–329.

    Article  CAS  PubMed  Google Scholar 

  41. Ge Y, Powell S, Van Roey M, McArthur JG . Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 2001; 97: 3733–3737.

    Article  CAS  PubMed  Google Scholar 

  42. Zhang YC, Powers M, Wasserfall C, Brusko T, Song S, Flotte T et al. Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity. Gene Therapy 2004; 11: 233–240.

    Article  CAS  PubMed  Google Scholar 

  43. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Cherel Y, Casadevall N et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 2004; 103: 3303–3304.

    Article  CAS  PubMed  Google Scholar 

  44. Gao G, Lebherz C, Weiner DJ, Grant R, Calcedo R, McCullough B et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 2004; 103: 3300–3302.

    Article  CAS  PubMed  Google Scholar 

  45. Budker V, Zhang G, Danko I, Williams P, Wolff J . The efficient expression of intravascularly delivered DNA in rat muscle. Gene Therapy 1998; 5: 272–276.

    Article  CAS  PubMed  Google Scholar 

  46. Gonin P, Arandel L, Van Wittenberghe L, Marais T, Perez N, Danos O . Femoral intra-arterial injection: a tool to deliver and assess recombinant AAV constructs in rodents whole hind limb. J Gene Med 2005; 7: 782–791.

    Article  CAS  PubMed  Google Scholar 

  47. Douar AM, Poulard K, Stockholm D, Danos O . Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 2001; 75: 1824–1833.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Xiao X, Li J, Samulski RJ . Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224–2232.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Li J, Samulski RJ, Xiao X . Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol 1997; 71: 5236–5243.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Allen JM, Halbert CL, Miller AD . Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6. Mol Ther 2000; 1: 88–95.

    Article  CAS  PubMed  Google Scholar 

  51. Snyder RO, Xiao X, Samulski RJ . Production of recombinant adeno-associated viral vectors. In: Dracopoli N, Hains J, Krof B, Moir D, Morton C, Seidman C, Seidman J, Smith D (eds). Current Protocols in Human Genetics. John Wiley and Sons: New York, 1996, pp 12.11.11–12.11.24.

    Google Scholar 

Download references

Acknowledgements

We thank Patrick Gonin for help with statistical analysis and Gabor Veres for critically reading the manuscript. We thank Karine Poulard for excellent technical assistance, Thibaut Marais and Laetitia Van Wittenberghe for animal experiments and Isabelle Adamski for histological analysis. We are grateful to Susan Cure for final reading of the manuscript. This work was performed with the financial support of the Association Française contre les Myopathies.

Author information

Authors and Affiliations

  1. Gene Therapy, CNRS UMR 8115, Généthon, Evry, France

    C Rivière, O Danos & A M Douar

Authors
  1. C Rivière
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O Danos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A M Douar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A M Douar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rivière, C., Danos, O. & Douar, A. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 13, 1300–1308 (2006). https://doi.org/10.1038/sj.gt.3302766

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302766

Keywords

This article is cited by

Search

Advanced search

Quick links